Botanical drug

Last updated
Sinecatechins, the first botanical drug approved by the US FDA, is an extract from the leaves of Camellia sinensis. Camellia sinensis - Kohler-s Medizinal-Pflanzen-025.jpg
Sinecatechins, the first botanical drug approved by the US FDA, is an extract from the leaves of Camellia sinensis.

A botanical drug is defined in the United States Federal Food, Drug, and Cosmetic Act as a botanical product that is marketed as diagnosing, mitigating, treating, or curing a disease; a botanical product in turn, is a finished, labeled product that contains ingredients from plants. Chemicals that are purified from plants, like paclitaxel, and highly purified products of industrial fermentation, like biopharmaceuticals, are not considered to be botanical products.

Contents

In 2006 the Food and Drug Administration approved the first botanical drug in the United States: sinecatechins, a green tea extract for genital warts. [1]

Definition

A botanical drug product is defined in the United States Federal Food, Drug, and Cosmetic Act (FD&C) as a botanical drug that is marketed as diagnosing, mitigating, treating, or curing a disease; a botanical product in turn, is a finished, labeled product that contains vegetable matter as ingredients. [2] :2–3 Chemicals that are purified from plants, like paclitaxel or artemisinin, and highly purified products of industrial fermentation, like biopharmaceuticals, are not considered to be botanical products. [2] :3

The FD&C act separately regulates uses of botanical products as food (including dietary supplements), medical devices (e.g., gutta-percha), and cosmetics. [2] :2

Regulation

Like other drugs, botanical drugs may be sold over the counter (OTC) or by prescription only. For OTC drugs, a monograph must be created by the company that wants to market the drug and then approved by the FDA, after which it is published in the Federal Register. For prescription drugs, a New Drug Application (NDA) must be filed with and approved by the FDA; clinical data included in the NDA is gathered under an Investigational New Drug Application which the FDA also must approve before clinical testing begins. [2] :3–4

Assessment of the safety and toxicity of botanical drugs in clinical trials, and in ensuring their quality once the drug is on the market, is complicated by the nature of the raw ingredients; problems arise in identifying the correct plants to harvest, in the quality of plants harvested, in their processing, and in the stability of the active components, which are often poorly understood. [3]

The FDA relies on a combination of tests and controls to ensure the identity and quality of botanical drugs. The tests include "fingerprinting" using spectroscopy or chromatography, chemical or biological assays, and process controls on raw material collection and processing. [2] :5 The standards are higher for botanical drugs than for extracts or plant matter used in dietary supplements. [2] :5

If the substance being developed as a botanical drug has been used in traditional medicine, it may be possible to begin initial, small clinical trials without conducting extensive toxicology testing. [2] :13 [4] [5] However, toxicity testing is required before beginning larger clinical trials and trials that will be used to get approval to sell a botanical drug. [4]

The endogenous Chinese pharmaceutical industry is made up mostly of companies that make herbal traditional chinese medicines and sell them over the counter; the US regulatory pathway is similar to that established by the China Food and Drug Administration. [6] :15,20

The European regulatory pathway is also similar. [7]

Examples

Croton lechleri bark with a few drops of dragon's blood Sangre de Grado.jpg
Croton lechleri bark with a few drops of dragon's blood

Market

As of 2012, the pharmaceutical industry had expressed strong interest in developing botanical drugs, with more than 500 applications pending at the FDA. [15] Part of the interest stems from a desire to address the Chinese market, where herbal medicines remain widely used and had $13 billion in sales in 2011. [15]

Related Research Articles

<span class="mw-page-title-main">Food and Drug Administration</span> Agency of the US Department of Health and Human Services

The United States Food and Drug Administration is a federal agency of the Department of Health and Human Services. The FDA is responsible for protecting and promoting public health through the control and supervision of food safety, tobacco products, caffeine products, dietary supplements, prescription and over-the-counter pharmaceutical drugs (medications), vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices (ERED), cosmetics, animal foods & feed and veterinary products.

<span class="mw-page-title-main">Pharmacology</span> Branch of biology concerning drugs

Pharmacology is a branch of medicine, biology and pharmaceutical sciences concerned with drug or medication action, where a drug may be defined as any artificial, natural, or endogenous molecule which exerts a biochemical or physiological effect on the cell, tissue, organ, or organism. More specifically, it is the study of the interactions that occur between a living organism and chemicals that affect normal or abnormal biochemical function. If substances have medicinal properties, they are considered pharmaceuticals.

<span class="mw-page-title-main">Stevia</span> Sweetener and sugar substitute

Stevia is a natural sweetener and sugar substitute derived from the leaves of the plant species Stevia rebaudiana, native to Paraguay and Brazil.

<span class="mw-page-title-main">Dietary supplement</span> Product that provides additional source of nutrients

A dietary supplement is a manufactured product intended to supplement one's diet by taking a pill, capsule, tablet, powder, or liquid. A supplement can provide nutrients either extracted from food sources or that are synthetic in order to increase the quantity of their consumption. The class of nutrient compounds includes vitamins, minerals, fiber, fatty acids, and amino acids. Dietary supplements can also contain substances that have not been confirmed as being essential to life, but are marketed as having a beneficial biological effect, such as plant pigments or polyphenols. Animals can also be a source of supplement ingredients, such as collagen from chickens or fish for example. These are also sold individually and in combination, and may be combined with nutrient ingredients. The European Commission has also established harmonized rules to help insure that food supplements are safe and appropriately labeled.

<span class="mw-page-title-main">Medication</span> Substance used to diagnose, cure, treat, or prevent disease

A medication is a drug used to diagnose, cure, treat, or prevent disease. Drug therapy (pharmacotherapy) is an important part of the medical field and relies on the science of pharmacology for continual advancement and on pharmacy for appropriate management.

<span class="mw-page-title-main">Generic drug</span> Pharmaceutical equivalent to a brand-name product

A generic drug is a pharmaceutical drug that contains the same chemical substance as a drug that was originally protected by chemical patents. Generic drugs are allowed for sale after the patents on the original drugs expire. Because the active chemical substance is the same, the medical profile of generics is equivalent in performance. A generic drug has the same active pharmaceutical ingredient (API) as the original, but it may differ in some characteristics such as the manufacturing process, formulation, excipients, color, taste, and packaging.

<i>Actaea racemosa</i> Species of plant

Actaea racemosa, the black cohosh, black bugbane, black snakeroot, rattle-top, or fairy candle, is a species of flowering plant of the family Ranunculaceae. It is native to eastern North America from the extreme south of Ontario to central Georgia, and west to Missouri and Arkansas. It grows in a variety of woodland habitats, and is often found in small woodland openings. The roots and rhizomes were used in traditional medicine by Native Americans. Its extracts are manufactured as herbal medicines or dietary supplements. Most dietary supplements containing black cohosh are not well-studied or recommended for safe and effective use in treating menopause symptoms or any disease. In contrast, some herbal medicinal products containing black cohosh extract hold a marketing authorization in several states of the European Union are well-studied and recommended for safe and effective use for the relief of menopausal symptoms such as hot flushes and profuse sweating attacks. Such differentiation between the product types seems to be important.

<span class="mw-page-title-main">Herbal medicine</span> Study and use of supposed medicinal properties of plants

Herbal medicine is the study of pharmacognosy and the use of medicinal plants, which are a basis of traditional medicine. With worldwide research into pharmacology, some herbal medicines have been translated into modern remedies, such as the anti-malarial group of drugs called artemisinin isolated from Artemisia annua, a herb that was known in Chinese medicine to treat fever. There is limited scientific evidence for the safety and efficacy of plants used in 21st century herbalism, which generally does not provide standards for purity or dosage. The scope of herbal medicine commonly includes fungal and bee products, as well as minerals, shells and certain animal parts. Herbal medicine is also called phytomedicine or phytotherapy.

<span class="mw-page-title-main">Medicinal plants</span> Plants or derivatives used to treat medical conditions in humans or animals

Medicinal plants, also called medicinal herbs, have been discovered and used in traditional medicine practices since prehistoric times. Plants synthesize hundreds of chemical compounds for various functions, including defense and protection against insects, fungi, diseases, and herbivorous mammals.

<span class="mw-page-title-main">Cannabidiol</span> Phytocannabinoid discovered in 1940

Cannabidiol (CBD) is a phytocannabinoid discovered in 1940. It is one of 113 identified cannabinoids in cannabis plants, along with tetrahydrocannabinol (THC), and accounts for up to 40% of the plant's extract. As of 2019, clinical research on CBD included studies related to anxiety, cognition, movement disorders, and pain, but there is insufficient high-quality evidence that cannabidiol is effective for these conditions. Nevertheless, CBD is an herbal dietary supplement promoted with unproven claims of particular therapeutic effects. The global market size for CBD was predicted to exceed US$47 billion by 2028.

Bioidentical hormone replacement therapy (BHRT), also known as bioidentical hormone therapy(BHT) or natural hormone therapy, is the use of hormones that are identical on a molecular level with endogenous hormones in hormone replacement therapy. It may also be combined with blood and saliva testing of hormone levels, and the use of pharmacy compounding to obtain hormones in an effort to reach a targeted level of hormones in the body. A number of claims by some proponents of BHT have not been confirmed through scientific testing. Specific hormones used in BHT include estrone, estradiol, progesterone, testosterone, dehydroepiandrosterone (DHEA), and estriol.

<span class="mw-page-title-main">Nabiximols</span> Specific cannabis extract

Nabiximols is a specific Cannabis extract that was approved in 2010 as a botanical drug in the United Kingdom. Nabiximols is sold as a mouth spray intended to alleviate neuropathic pain, spasticity, overactive bladder, and other symptoms of multiple sclerosis; it was developed by the UK company GW Pharmaceuticals. In 2019 it was proposed that following application of the spray, nabiximols is washed away from the oral mucosa by the saliva flow and ingested into the stomach, with subsequent absorption from the gastro-intestinal tract. Nabiximols is a combination drug standardized in composition, formulation, and dose. Its principal active cannabinoid components are the cannabinoids: tetrahydrocannabinol (THC) and cannabidiol (CBD). Each spray delivers a dose of 2.7 mg THC and 2.5 mg CBD.

<span class="mw-page-title-main">Bazedoxifene</span> Chemical compound

Bazedoxifene, used as bazedoxifene acetate, is a medication for bone problems and possibly for cancer. It is a third-generation selective estrogen receptor modulator (SERM). Since late 2013 it has had U.S. FDA approval for bazedoxifene as part of the combination drug Duavee in the prevention of postmenopausal osteoporosis. It is also being studied for possible treatment of breast cancer and pancreatic cancer.

<span class="mw-page-title-main">Drug development</span> Process of bringing a new pharmaceutical drug to the market

Drug development is the process of bringing a new pharmaceutical drug to the market once a lead compound has been identified through the process of drug discovery. It includes preclinical research on microorganisms and animals, filing for regulatory status, such as via the United States Food and Drug Administration for an investigational new drug to initiate clinical trials on humans, and may include the step of obtaining regulatory approval with a new drug application to market the drug. The entire process – from concept through preclinical testing in the laboratory to clinical trial development, including Phase I–III trials – to approved vaccine or drug typically takes more than a decade.

<span class="mw-page-title-main">Femarelle</span> Trademarked mixture

Femarelle is a dietary supplement that is a mixture of DT56a and flaxseed powder, that may act as a selective estrogen receptor modulator (SERM). In 2008 an application was submitted to the European Food Safety Authority to market Femarelle with a health claim, namely that it can reduce the risk for osteoporosis and other bone disorders; the EFSA found that "the food/constituent for which the claim is made, i.e. Femarelle, has not been sufficiently characterised" and that " a cause and effect relationship has not been established between the consumption of Femarelle and increased BMD, increased bone formation, or decreased risk of osteoporosis or other bone disorders in post-menopausal women."

<span class="mw-page-title-main">Bionovo</span> Biotechnology company

Bionovo was an American biotechnology company focused on the discovery and development of botanically derived treatments for women's health and cancer based in Emeryville, California. The company had multiple drug candidates in U.S. Food and Drug Administration (FDA) clinical trials- Menerba a selective estrogen receptor beta agonist for hot flashes associated with menopause Seala a selective estrogen receptor beta agonist for menopausal vaginal dryness and Bezielle for advanced breast cancer. The company has ceased activity after filing for Chapter 7 bankruptcy protection in California. Bionovo's stock is no longer listed.

<span class="mw-page-title-main">Wyeth</span> American pharmaceutical company (1860-2009)

Wyeth, LLC was an American pharmaceutical company. The company was founded in Philadelphia, Pennsylvania, in 1860 as John Wyeth and Brother. It was later known, in the early 1930s, as American Home Products, before being renamed to Wyeth in 2002. Its headquarters moved to Collegeville, Pennsylvania and Madison, New Jersey, before they were consolidated with Pfizer's in New York City after the 2009 merger. Most of Wyeth's pharmaceutical assets were acquired by Pfizer in 2009, while its infant and maternal nutrition business was acquired by Nestlé in 2012.

Menerba, also known as Menopause Formula 101 (MF-101), is a botanical drug candidate that acts as a selective estrogen receptor modulator (SERM) which is being studied for its potential to relieve hot flashes associated with menopause. Menerba, an estrogen receptor beta (ERβ) agonist (ERBA), is part of a new class of receptor subtype-selective estrogens, which is selective in transcriptional regulation to one of the two known estrogen receptor (ER) subtypes. Menerba consists of 22 herbs that have been used historically in traditional Chinese medicine.

<span class="mw-page-title-main">GW Pharmaceuticals</span>

GW Pharmaceuticals is a British pharmaceutics company known for its multiple sclerosis treatment product nabiximols which was the first natural cannabis plant derivative to gain market approval in any country. Another cannabis-based product, Epidiolex, was approved for treatment of epilepsy by the US Food and Drug Administration in 2018. It is a subsidiary of Jazz Pharmaceuticals.

<span class="mw-page-title-main">Ospemifene</span> Chemical compound

Ospemifene is an oral medication indicated for the treatment of dyspareunia – pain during sexual intercourse – encountered by some women, more often in those who are post-menopausal. Ospemifene is a selective estrogen receptor modulator (SERM) acting similarly to an estrogen on the vaginal epithelium, building vaginal wall thickness which in turn reduces the pain associated with dyspareunia. Dyspareunia is most commonly caused by "vulvar and vaginal atrophy."

References

  1. 1 2 Chen ST; et al. (Oct 2008). "Commentary: New therapies from old medicines" (PDF). Nat Biotechnol. 26 (10): 1077–83. doi:10.1038/nbt1008-1077. PMID   18846070. S2CID   205271440.
  2. 1 2 3 4 5 6 7 U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER). June 2004. Guidance for Industry: Botanical Drug Products
  3. Jordan SA, Cunningham DG, Marles RJ (Mar 2010). "Assessment of herbal medicinal products: challenges, and opportunities to increase the knowledge base for safety assessment". Toxicol Appl Pharmacol. 243 (2): 198–216. doi:10.1016/j.taap.2009.12.005. PMID   20018204.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  4. 1 2 Wu KM, Ghantous H, Birnkrant DB (Aug 2008). "Current regulatory toxicology perspectives on the development of herbal medicines to prescription drug products in the United States". Food Chem Toxicol. 46 (8): 2606–10. doi:10.1016/j.fct.2008.05.029. PMID   18614266.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  5. Wu KM; et al. (Feb 2010). "Current regulatory perspectives on genotoxicity testing for botanical drug product development in the U.S.A." Regul Toxicol Pharmacol. 56 (1): 1–3. doi:10.1016/j.yrtph.2009.09.012. PMID   19782117.
  6. Deloitte, 2011 The next phase:Opportunities in China's pharmaceuticals market
  7. Poluzzi E; et al. (2014). ""Phytoestrogens in postmenopause " the state of the art from a chemical, pharmacological and regulatory perspective". Curr Med Chem. 21 (4): 417–36. doi:10.2174/09298673113206660297. PMC   3963458 . PMID   24164197.
  8. 1 2 FDA: What is a Botanical Drug? (2017-08-14)
  9. United States Adopted Names Council: Statement on a nonproprietary name
  10. Multiple Sclerosis Trust. October 2014 Sativex (nabiximols) - factsheet
  11. Stovall, DW; Pinkerton, JV (2009). "MF-101, an estrogen receptor beta agonist for the treatment of vasomotor symptoms in peri- and postmenopausal women". Current Opinion in Investigational Drugs. 10 (4): 365–71. PMID   19337958.
  12. Grady, Deborah; Sawaya, George F.; Johnson, Karen C.; Koltun, William; Hess, Rachel; Vittinghoff, Eric; Kristof, Margaret; Tagliaferri, Mary; et al. (2009). "MF101, a selective estrogen receptor β modulator for the treatment of menopausal hot flushes". Menopause. 16 (3): 458–65. doi:10.1097/gme.0b013e31818e64dd. PMID   19182698. S2CID   31985236.
  13. Bionovo press release, September 23, 2010 FDA Approves Manufacturing Plan for Menerba, Bionovo's Menopausal Hot Flash Drug Candidate
  14. Bionovo. Menerba page at Bionovo Page accessed May 2, 2015
  15. 1 2 Daryl Loo for Bloomberg News. December 11, 2012 Ancient Chinese Cures Seen Helping Drugmaker Pipelines